Purple Biotech (PPBT) Cash from Investing Activities (2017 - 2026)

Purple Biotech (PPBT) has 10 years of Cash from Investing Activities data on file, last reported at $45000.0 in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 82.49% year-over-year to $45000.0 in Q1 2026; TTM through Mar 2026 was $420000.0, a 7.49% decrease from a year earlier, with the FY2025 full-year figure at $632000.0, up 24.17% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $45000.0, up from -$104000.0 in the prior quarter.
• Over the last five years, Cash from Investing Activities for PPBT reached as high as $17.7 million in Q1 2022 and fell as low as -$6.0 million in Q2 2022.
• Historically, Cash from Investing Activities has averaged $2.1 million across 5 years, with a median of $177000.0 in 2022.
• Across the five-year window, Cash from Investing Activities jumped 1249.28% in 2022 and tumbled 373.68% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $8.0 million in 2022, then slumped by 99.07% to $74000.0 in 2023, then sank by 48.65% to $38000.0 in 2024, then sank by 373.68% to -$104000.0 in 2025, then surged by 143.27% to $45000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $45000.0 in Q1 2026, -$104000.0 in Q4 2025, and $372000.0 in Q3 2025.